Adocia’s technology backed again (at a higher price) by Lilly

News published on December Friday 19, 2014
Share on

Diabetes : Adocia’s technology backed again (at a higher price) by Lilly – read across
This morning Adocia and Lilly announced that they had renewed their partnership to develop BioChaperone Lispro, an ultra-fast acting insulin based on Lilly’s short-acting insulin lispro (Humalog) and Adocia’s technology. The product should compete with Novo-Nordisk’s NN1218 which entered phase III in 2014 and should be filed with the regulatory authorities late in 2015. Phase II data are very compelling. Adocia will receive an upfront payment of USD50m, up to USD520m in milestones and tiered royalties on sales. Interestingly the company has other interesting assets that could be available for partnerships in the coming months. Other companies in the field of Diabetes could be well inspired to have a close look to what Adocia is doing.

For more information, please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities